Vaccines within vaccines

References

• Dudding BA, Top FH Jr., Winter PE, Buescher EL, Lamson TH, Leibovitz A. Acute respiratory disease in military trainees: the adenovirus surveillance program, 1966-1971. Am J Epidemiol 1973; 97:187 - 98; PMID: 4348245
   PubMed Web of Science ®Google Scholar
• Kitchen LW, Vaughn DW. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine 2007; 25:7017 - 30; http://dx.doi.org/10.1016/j.vaccine.2007.07.030; PMID: 17728025
   PubMed Web of Science ®Google Scholar
• Gaydos CA, Gaydos JC. Adenovirus vaccines in the U.S. military. Mil Med 1995; 160:300 - 4; PMID: 7659229
   PubMed Web of Science ®Google Scholar
• Buescher EL. Respiratory disease and the adenoviruses. Med Clin North Am 1967; 51:769 - 79; PMID: 4290351
   PubMed Web of Science ®Google Scholar
• Hyer RN, Howell MR, Ryan MAK, Gaydos JC. Cost-effectiveness analysis of reacquiring and using adenovirus types 4 and 7 vaccines in naval recruits. Am J Trop Med Hyg 2000; 62:613 - 8; PMID: 11289673
   PubMed Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13:238 - 50; http://dx.doi.org/10.1016/S1473-3099(12)70345-6; PMID: 23369412
   PubMed Web of Science ®Google Scholar
• Hoke CH Jr., Snyder CE Jr.. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine 2013; 31:1623 - 32; http://dx.doi.org/10.1016/j.vaccine.2012.12.029; PMID: 23291475
   PubMed Web of Science ®Google Scholar
• Santra S, Sun Y, Korioth-Schmitz B, Fitzgerald J, Charbonneau C, Santos G, Seaman MS, Ratcliffe SJ, Montefiori DC, Nabel GJ, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 2009; 27:5837 - 45; http://dx.doi.org/10.1016/j.vaccine.2009.07.050; PMID: 19660588
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Nehete BP, Buchl SJ, Palmer D, Montefiori DC, Ng P, Sastry KJ, Barry MA. Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses 2009; 1:920 - 38; http://dx.doi.org/10.3390/v1030920; PMID: 20107521
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, Ng P, Sastry KJ, Barry MA. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 2009; 4:e5059; http://dx.doi.org/10.1371/journal.pone.0005059; PMID: 19333387
   PubMed Web of Science ®Google Scholar
• Weaver EA, Rubrum AM, Webby RJ, Barry MA. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One 2011; 6:e18314; http://dx.doi.org/10.1371/journal.pone.0018314; PMID: 21464940
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005; 79:9694 - 701; http://dx.doi.org/10.1128/JVI.79.15.9694-9701.2005; PMID: 16014931
   PubMed Web of Science ®Google Scholar
• Tan WG, Jin HT, West EE, Penaloza-MacMaster P, Wieland A, Zilliox MJ, McElrath MJ, Barouch DH, Ahmed R. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 2013; 87:1359 - 72; http://dx.doi.org/10.1128/JVI.02055-12; PMID: 23175355
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654 - 63; http://dx.doi.org/10.1128/JVI.02696-06; PMID: 17329340
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng’ang’a D, Brandariz KL, Abbink P, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011; 29:5203 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.05.025; PMID: 21619905
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.10.145; PMID: 19925902
   PubMed Web of Science ®Google Scholar
• Ludwig SL, Brundage JF, Kelley PW, Nang R, Towle C, Schnurr DP, Crawford-Miksza L, Gaydos JC. Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis 1998; 178:1776 - 8; http://dx.doi.org/10.1086/314498; PMID: 9815232
   PubMed Web of Science ®Google Scholar
• Chengalvala M, Lubeck MD, Davis AR, Mizutani S, Molnar-Kimber K, Morin J, Hung PP. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine 1991; 9:485 - 90; http://dx.doi.org/10.1016/0264-410X(91)90033-3; PMID: 1832806
   PubMed Web of Science ®Google Scholar
• Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, Molnar-Kimber K, Mason BB, Bhat BM, Mizutani S, Hung PP, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 1989; 86:6763 - 7; http://dx.doi.org/10.1073/pnas.86.17.6763; PMID: 2570422
   PubMed Web of Science ®Google Scholar
• Natuk RJ, Lubeck MD, Chanda PK, Chengalvala M, Wade MS, Murthy SC, Wilhelm J, Vernon SK, Dheer SK, Mizutani S, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 1993; 9:395 - 404; http://dx.doi.org/10.1089/aid.1993.9.395; PMID: 8318268
   PubMed Web of Science ®Google Scholar
• Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, Guenther B, Garduno F, Jow L, Snarsky V, et al. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 2012; 7:e31177; http://dx.doi.org/10.1371/journal.pone.0031177; PMID: 22363572
   PubMed Web of Science ®Google Scholar
• Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, Mizutani S, Murphy BR, Collins PL, Chanock RM, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J Infect Dis 1992; 166:769 - 75; http://dx.doi.org/10.1093/infdis/166.4.769; PMID: 1527411
   PubMed Web of Science ®Google Scholar
• Artenstein AW. Vaccines for military use. Vaccine 2009; 27:Suppl 4 D16 - 22; http://dx.doi.org/10.1016/j.vaccine.2009.07.044; PMID: 19837279
   PubMedGoogle Scholar
• Wold WS, Gooding LR. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991; 184:1 - 8; http://dx.doi.org/10.1016/0042-6822(91)90815-S; PMID: 1831308
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Delgado-Lopez F, Horwitz MS. Inhibition of chemokine expression by adenovirus early region three (E3) genes. J Virol 2002; 76:8236 - 43; http://dx.doi.org/10.1128/JVI.76.16.8236-8243.2002; PMID: 12134029
   PubMed Web of Science ®Google Scholar
• Horwitz MS, Efrat S, Christen U, von Herrath MG, Oldstone MB. Adenovirus E3 MHC inhibitory genes but not TNF/Fas apoptotic inhibitory genes expressed in beta cells prevent autoimmune diabetes. Proc Natl Acad Sci U S A 2009; 106:19450 - 4; http://dx.doi.org/10.1073/pnas.0910648106; PMID: 19887639
   PubMed Web of Science ®Google Scholar
• Koehler DR, Martin B, Corey M, Palmer D, Ng P, Tanswell AK, Hu J. Readministration of helper-dependent adenovirus to mouse lung. Gene Ther 2006; 13:773 - 80; http://dx.doi.org/10.1038/sj.gt.3302712; PMID: 16437131
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13:1887 - 900; http://dx.doi.org/10.1089/104303402760372972; PMID: 12396620
   PubMed Web of Science ®Google Scholar
• Kuzmin AI, Galenko O, Eisensmith RC. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors. Mol Ther 2001; 3:293 - 301; http://dx.doi.org/10.1006/mthe.2000.0258; PMID: 11273770
   PubMed Web of Science ®Google Scholar
• Nagao S, Kuriyama S, Okuda H, Tominaga K, Nakatani T, Tsujinoue H, Yoshiji H, Fukui H. Adenovirus-mediated gene transfer into tumors: evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice. Int J Oncol 2001; 18:57 - 65; PMID: 11115539
   PubMed Web of Science ®Google Scholar
• Chirmule N, Raper SE, Burkly L, Thomas D, Tazelaar J, Hughes JV, Wilson JM. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol 2000; 74:3345 - 52; http://dx.doi.org/10.1128/JVI.74.7.3345-3352.2000; PMID: 10708452
   PubMed Web of Science ®Google Scholar
• McClane SJ, Chirmule N, Burke CV, Raper SE. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum Gene Ther 1997; 8:2207 - 16; http://dx.doi.org/10.1089/hum.1997.8.18-2207; PMID: 9449374
   PubMed Web of Science ®Google Scholar
• Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17:96 - 104; http://dx.doi.org/10.1038/nm.2270; PMID: 21151137
   PubMed Web of Science ®Google Scholar
• Hartman ZC, Appledorn DM, Serra D, Glass O, Mendelson TB, Clay TM, Amalfitano A. Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology 2008; 374:453 - 67; http://dx.doi.org/10.1016/j.virol.2008.01.017; PMID: 18280530
   PubMed Web of Science ®Google Scholar
• Oglesby TJ, Allen CJ, Liszewski MK, White DJ, Atkinson JP. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 1992; 175:1547 - 51; http://dx.doi.org/10.1084/jem.175.6.1547; PMID: 1588280
   PubMed Web of Science ®Google Scholar
• Wang H, Beyer I, Persson J, Song H, Li Z, Richter M, Cao H, van Rensburg R, Yao X, Hudkins K, et al. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol 2012; 86:6286 - 302; http://dx.doi.org/10.1128/JVI.00205-12; PMID: 22457526
   PubMed Web of Science ®Google Scholar
• Kuschner RA, Russell KL, Abuja M, Bauer KM, Faix DJ, Hait H, Henrick J, Jacobs M, Liss A, Lynch JA, et al, Adenovirus Vaccine Efficacy Trial Consortium. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine 2013; 31:2963 - 71; http://dx.doi.org/10.1016/j.vaccine.2013.04.035; PMID: 23623865
   PubMed Web of Science ®Google Scholar
• Nam JH, Na HN, Atkinson RL, Dhurandhar NV. (2013) Genomic stability of adipogenic human adenovirus 36. Int J Obes (Lond).
   Google Scholar
• Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413 - 31; http://dx.doi.org/10.1016/S0140-6736(12)60034-8; PMID: 22305225
   PubMed Web of Science ®Google Scholar
• Fukuda MM, Klein TA, Kochel T, Quandelacy TM, Smith BL, Villinski J, Bethell D, Tyner S, Se Y, Lon C, et al, AFHSC-GEIS Malaria and Vector Borne Infections Writing Group. Malaria and other vector-borne infection surveillance in the U.S. Department of Defense Armed Forces Health Surveillance Center-Global Emerging Infections Surveillance program: review of 2009 accomplishments. BMC Public Health 2011; 11:Suppl 2 S9; http://dx.doi.org/10.1186/1471-2458-11-S2-S9; PMID: 21388569
   PubMedGoogle Scholar
• Whitman TJ, Coyne PE, Magill AJ, Blazes DL, Green MD, Milhous WK, Burgess TH, Freilich D, Tasker SA, Azar RG, et al. An outbreak of Plasmodium falciparum malaria in U.S. Marines deployed to Liberia. Am J Trop Med Hyg 2010; 83:258 - 65; http://dx.doi.org/10.4269/ajtmh.2010.09-0774; PMID: 20682864
   PubMed Web of Science ®Google Scholar
• Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013; 8:e55571; http://dx.doi.org/10.1371/journal.pone.0055571; PMID: 23457473
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263 - 71; http://dx.doi.org/10.1128/JVI.77.15.8263-8271.2003; PMID: 12857895
   PubMed Web of Science ®Google Scholar
• Berge TO, England B, Mauris C, Shuey HE, Lennette EH. Etiology of acute respiratory disease among service personnel at Fort Ord, California. Am J Hyg 1955; 62:283 - 94; PMID: 13268418
   PubMed Web of Science ®Google Scholar
• Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003; 41:5046 - 52; http://dx.doi.org/10.1128/JCM.41.11.5046-5052.2003; PMID: 14605137
   PubMed Web of Science ®Google Scholar